News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,562 Results
Type
Article (14894)
Company Profile (299)
Press Release (266363)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79834)
Career Advice (162)
Deals (13336)
Drug Delivery (39)
Drug Development (50696)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145071)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6030)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43663)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31642)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51657)
Executive appointments (621)
FDA (7583)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6614)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26649)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15473)
Phase 2 (20285)
Phase 3 (12819)
Pipeline (3239)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1447)
Recruiting (12)
Regulatory (9891)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1205)
Last 365 days (17796)
2026 (1651)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18250)
Australia (3110)
California (7074)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39155)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23320)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,562 Results for "arrakis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)
December 3, 2025
·
4 min read
Press Releases
Arrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025
March 10, 2025
·
2 min read
Press Releases
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy
December 4, 2024
·
5 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Mergers & acquisitions
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia.
January 7, 2026
·
1 min read
·
Tristan Manalac
Genetown
Arrakis Therapeutics to Participate in Upcoming May 2022 Investor Conferences
Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: 2022 RBC Capital Markets Global Healthcare Conference Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a fireside chat on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.
May 10, 2022
·
1 min read
Genetown
Arrakis Therapeutics to Participate in Upcoming Investor Conferences - Mar 31, 2022
Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m.
March 31, 2022
·
1 min read
Business
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
Arrakis Therapeutics today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.
December 6, 2021
·
3 min read
Genetown
Arrakis Therapeutics to Present at Jefferies Healthcare Conference - June 01, 2022
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 3:30 p.m. ET in New York.
June 1, 2022
·
1 min read
Genetown
Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference
Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET.
February 8, 2022
·
1 min read
1 of 28,157
Next
